CureusJul 26, 2026

How Metabolism and Hormones Work Together: A New View on Reproduction and Metabolism in the GLP-1 Treatment Era

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 27, 2026

Abstract

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder among reproductive-age women worldwide.

PCOS may be more accurately described as polycystic-morphology ovary syndrome (PMOS) due to its diverse pathophysiology.
Management of PCOS is often fragmented across different specialties, including gynecology, endocrinology, and dermatology.
Contraceptive choices for women with PCOS may need to consider metabolic status, insulin resistance, and cardiovascular risks.
The introduction of glucagon-like peptide-1 (GLP-1) receptor agonists raises new questions about their effects on hormonal contraception and ovarian function.
A new framework, the Reproductive-Metabolic Axis (RMA), is proposed for understanding PCOS/PMOS as an integrated condition.

Simplified

Polycystic ovary syndrome (PCOS), proposed by some investigators to be more accurately termed polycystic-morphology ovary syndrome (PMOS), reflecting its heterogeneous and not universally cystic pathophysiology, remains the most prevalent endocrine disorder among reproductive-age women worldwide. Despite this, its clinical management continues to be fragmented along specialty lines, with gynecologists addressing menstrual irregularity and contraception, endocrinologists managing insulin resistance and metabolic risk, and dermatologists treating hyperandrogenic manifestations. This editorial proposes the Reproductive-Metabolic Axis (RMA) as a unifying conceptual framework for understanding PCOS/PMOS beyond its phenotypic surface. We argue that contraceptive decision-making in women with PCOS/PMOS cannot be separated from metabolic status, insulin resistance, androgen excess, and cardiovascular risk profiling. In the glucagon-like peptide-1 (GLP-1) receptor agonist era, which has transformed the management of obesity and insulin resistance, new clinical questions arise regarding the interaction between incretin-based therapies, hormonal contraception, and ovarian function restoration. The present editorial does not propose a validated therapeutic protocol, but rather a hypothesis-generating framework that invites further clinical investigation into whether integrated reproductive-metabolic management improves outcomes for women with PCOS/PMOS.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

0%of authors

0 of 2

authors report competing interests

2 report none

PubMed

How Metabolism and Hormones Work Together: A New View on Reproduction and Metabolism in the GLP-1 Treatment Era

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief